Newron Pharmaceuticals S.p.A. · ISIN: IT0004147952 · EQS - Company News

Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories

Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories Newron will receive up to a maximum of €117 million from an upfront payment, development milestones and commercialization milestones, and up to double-digit tiered royalties on net sales Evenamide is a unique modulator of the excessive release of glutamate in treatment resistant schizophrenia (TRS) and poorly responding patients with schizophrenia Newron expect...

SIX:NWRN Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Newron Pharmaceuticals S.p.A.

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
13 December 2024 07:00AM
Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories
IT0004147952
Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories Newron will receive up to a maximum of €117 million from an upfront payment, development milestones and commercialization milestones, and up to double-digit tiered royalties on net sales Evenamide is a unique modul...
Newron Pharmaceuticals S.p.A.
About the publication
19 September 2024 07:00AM
Newron presents H1 2024 results and provides business update
IT0004147952
Newron presents H1 2024 results and provides business update  Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial...
Newron Pharmaceuticals S.p.A.
About the publication
19 September 2024 07:00AM
Newron presents H1 2024 results and provides business update
IT0004147952
Newron presents H1 2024 results and provides business update  Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial...
Newron Pharmaceuticals S.p.A.
About the publication
25 June 2024 05:45PM
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
IT0004147952
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City  Clinical results and new findings of mechanism of action indicate evenamide would be uniquely effective in patients with treatment resistant schizophrenia  Leading schizophrenia experts predict earlier use of evenamide would benefit patients with inadequate response Evena...
Newron Pharmaceuticals S.p.A.
About the publication
18 June 2024 05:45PM
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
IT0004147952
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City   Three of the world’s leading key opinion leaders (KOL) in neuroscience and schizophrenia to review and present findings on Newron’s evenamide program for treatment-resistant schizophrenia   The company will host a Live-Webcast of the event, beginning at 9:00 AM EDT (2...
Newron Pharmaceuticals S.p.A.
About the publication
05 June 2024 05:45PM
Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
IT0004147952
Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City   New hope emerges for treatment-resistant schizophrenia: leading KOLs to reveal insights into the neurobiology of treatment for both poorly responding and treatment-resistant patients Company to lay out the roadmap for US and EU registration for evenamide Milan...
Newron Pharmaceuticals S.p.A.
About the publication
13 May 2024 07:00AM
Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
IT0004147952
Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings  Benefit on efficacy measures increased over time, suggesting larger ...
Newron Pharmaceuticals S.p.A.
About the publication
30 April 2024 07:00AM
Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
IT0004147952
 Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified Glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizoph...
Newron Pharmaceuticals S.p.A.
About the publication
08 April 2024 07:00AM
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
IT0004147952
 Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year Presentatio...
Newron Pharmaceuticals S.p.A.
About the publication
19 March 2024 07:00AM
Newron presents 2023 financial results and provides 2024 outlook
IT0004147952
Newron presents 2023 financial results and provides 2024 outlook Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financ...
Newron Pharmaceuticals S.p.A.
About the publication
15 March 2024 07:00AM
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
IT0004147952
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement   EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages...
Newron Pharmaceuticals S.p.A.
About the publication
14 March 2024 06:32PM
 Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million 
IT0004147952
 Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares Proceeds of up to EUR 15.0* million  Milan, Italy, March 14, 2024, 17:45 CET – Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients ...
Newron Pharmaceuticals S.p.A.
About the publication
04 January 2024 07:00AM
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
IT0004147952
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS) Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF) More than 70% of patients experienced clinically im...
Newron Pharmaceuticals S.p.A.
About the publication
29 December 2023 07:00AM
Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
IT0004147952
 Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide   290 patients participate at study centers in Europe, Asia and Latin America  Results from the study are expected in March 2024  Milan, Italy, December 29, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.  (“Newron”) (SIX: NWRN, XETRA: NP5)...
Newron Pharmaceuticals S.p.A.
About the publication
09 October 2023 12:45PM
Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
IT0004147952
Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria 40% of patients no longer met TRS severity criteria Company presented data from study in treatment resistant schizophrenia (TRS) confirming therapeutic durability and efficacy at the 36th ECNP Congress in Bar...
Newron Pharmaceuticals S.p.A.
About the publication
04 October 2023 07:00AM
Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
IT0004147952
Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress Poster presentations will include the full results from all 161 patients randomized in study 014 at the six-month time point from extension study 015, a Phase II trial evalu...
Newron Pharmaceuticals S.p.A.
About the publication
02 October 2023 07:00AM
 Newron appoints Margarita Chavez as board advisor
IT0004147952
 Newron appoints Margarita Chavez as board advisor Margarita Chavez, former Managing Director at AbbVie Ventures, to be nominated for election to the Board of Directors at the Ordinary AGM 2024 Milan, Italy, October 2, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development ...
Newron Pharmaceuticals S.p.A.
About the publication
04 August 2023 07:00AM
Newron announces H1 2023 results and provides R&D update
IT0004147952
Newron announces H1 2023 results and provides R&D update Milan, Italy, August 4, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial resul...
Newron Pharmaceuticals S.p.A.
About the publication
15 May 2023 07:00AM
Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
IT0004147952
Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS) Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data from first 100 patient...
Newron Pharmaceuticals S.p.A.
About the publication
15 May 2023 07:00AM
Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
IT0004147952
Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS) Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data from first 100 patient...
Newron Pharmaceuticals S.p.A.
About the publication
03 May 2023 07:00AM
Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
IT0004147952
Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)  Further data from study 014/015 of evenamide in treatment-resistant schizophrenia (TRS) confirms potentially relevant role of glutamatergic release modification when added to TRS patients no...
Newron Pharmaceuticals S.p.A.
About the publication
03 May 2023 07:00AM
Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
IT0004147952
Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)  Further data from study 014/015 of evenamide in treatment-resistant schizophrenia (TRS) confirms potentially relevant role of glutamatergic release modification when added to TRS patients no...
Newron Pharmaceuticals S.p.A.
About the publication
02 May 2023 07:00AM
Newron announces Senior Management Team changes
IT0004147952
Newron announces Senior Management Team changes  Milan, Italy, May 2, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that the Board of Directors has a...
Newron Pharmaceuticals S.p.A.
About the publication
02 May 2023 07:00AM
Newron announces Senior Management Team changes
IT0004147952
Newron announces Senior Management Team changes  Milan, Italy, May 2, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that the Board of Directors has a...
Newron Pharmaceuticals S.p.A.
About the publication
18 April 2023 12:15PM
Newron announces AGM 2023 results  
IT0004147952
Newron announces AGM 2023 results   Milan, Italy, April 18, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces that its shareholders approved all motions on the age...
Newron Pharmaceuticals S.p.A.
About the publication
28 March 2023 12:30PM
Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
IT0004147952
Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry  Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data suggest a new strategy for the management of TRS patients in the fu...
Newron Pharmaceuticals S.p.A.
About the publication
28 March 2023 12:30PM
Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
IT0004147952
Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry  Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data suggest a new strategy for the management of TRS patients in the fu...
Newron Pharmaceuticals S.p.A.
About the publication
20 March 2023 07:00AM
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
IT0004147952
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia Results from all 161 patients at the 6-week primary endpoint show a statistically significant improvement over baseline in all efficacy measures   Results consistent wi...
Newron Pharmaceuticals S.p.A.
About the publication
20 March 2023 07:00AM
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
IT0004147952
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia Results from all 161 patients at the 6-week primary endpoint show a statistically significant improvement over baseline in all efficacy measures   Results consistent wi...
Newron Pharmaceuticals S.p.A.
About the publication
17 March 2023 07:00AM
Newron to present at the 31st European Congress of Psychiatry  
IT0004147952
Newron to present at the 31st European Congress of Psychiatry Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia  Milan, Italy, March 17, 2023, 7am...
Newron Pharmaceuticals S.p.A.
About the publication
17 March 2023 07:00AM
Newron to present at the 31st European Congress of Psychiatry  
IT0004147952
Newron to present at the 31st European Congress of Psychiatry Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia  Milan, Italy, March 17, 2023, 7am...
Newron Pharmaceuticals S.p.A.
About the publication
14 March 2023 07:00AM
Newron announces 2022 financial results and provides outlook for 2023
IT0004147952
Newron announces 2022 financial results and provides outlook for 2023 Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its fina...
Newron Pharmaceuticals S.p.A.
About the publication
14 March 2023 07:00AM
Newron announces 2022 financial results and provides outlook for 2023
IT0004147952
Newron announces 2022 financial results and provides outlook for 2023 Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its fina...
Newron Pharmaceuticals S.p.A.
About the publication
16 February 2023 07:00AM
Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
IT0004147952
Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia   Highly compelling, statistically significant, clinically meaningful improvement in assessments of symptoms of psychosis, disease severity and global evaluation at ...
Newron Pharmaceuticals S.p.A.
About the publication
16 February 2023 07:00AM
Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
IT0004147952
Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia   Highly compelling, statistically significant, clinically meaningful improvement in assessments of symptoms of psychosis, disease severity and global evaluation at ...
Newron Pharmaceuticals S.p.A.
About the publication
03 January 2023 07:00AM
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
IT0004147952
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia   Statistically significant, clinically meaningful improvements over baseline were seen across efficacy endpoints after six months; continued improvement was seen when co...
Newron Pharmaceuticals S.p.A.
About the publication
15 September 2022 07:00AM
Newron provides H1 2022 results and updates on R&D and business activities
IT0004147952
Milan, Italy, September 15, 2022, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half year ended Jun...
Newron Pharmaceuticals S.p.A.
About the publication
15 September 2022 07:00AM
Newron provides H1 2022 results and updates on R&D and business activities
IT0004147952
Milan, Italy, September 15, 2022, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half year ended Jun...
Newron Pharmaceuticals S.p.A.
About the publication
01 July 2022 07:00AM
Newron extends Senior Management team and strengthens commitment to ESG
IT0004147952
Newron extends Senior Management team and strengthens commitment to ESG Milan, Italy, July 1, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it is ex...
Newron Pharmaceuticals S.p.A.
About the publication
01 July 2022 07:00AM
Newron extends Senior Management team and strengthens commitment to ESG
IT0004147952
Newron extends Senior Management team and strengthens commitment to ESG Milan, Italy, July 1, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it is ex...
Newron Pharmaceuticals S.p.A.
About the publication
07 June 2022 07:00AM
Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
IT0004147952
Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology   Interim results show improved symptoms of psychosis in patients with chronic TRS Study 014 represents first international trial of a New Chemical Entity (NCE) anti...
Newron Pharmaceuticals S.p.A.
About the publication
05 April 2022 11:45AM
Newron announces AGM 2022 results
IT0004147952
Newron announces AGM 2022 results Milan, Italy - April 5, 2022 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that its shareholders approved all motions on the agenda of t...
Newron Pharmaceuticals S.p.A.
About the publication
15 March 2022 07:00AM
Newron announces 2021 financial results and provides outlook for 2022
IT0004147952
Newron announces 2021 financial results and provides outlook for 2022 Milan, Italy, March 15, 2022, 7 am CET - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its fina...
Newron Pharmaceuticals S.p.A.
About the publication
01 December 2021 05:46PM
Change in Newron Board of Directors
IT0004147952
Ad hoc announcement pursuant to Art. 53 LR Milan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ('Newron', SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Robert Leslie Holland has informed the Board...
Newron Pharmaceuticals SpA
About the publication
01 December 2021 05:45PM
Change in Newron Board of Directors
IT0004147952
Change in Newron Board of Directors Milan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ("Newron", SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Robert Leslie Holland has informed the Board of Dir...
Newron Pharmaceuticals S.p.A.
About the publication
18 October 2021 05:45PM
Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)
IT0004147952
Ad hoc announcement pursuant to Art. 53 SIX Listing Rules Milan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received ...
Newron Pharmaceuticals SpA
About the publication
18 October 2021 05:45PM
Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)
IT0004147952
Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB) Milan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous syste...
Newron Pharmaceuticals S.p.A.
About the publication
16 September 2021 07:01AM
Newron announces Half-Year 2021 results
IT0004147952
Ad hoc announcement pursuant to Art. 53 LR Milan, Italy, September 16, 2021, 07:00 am CEST - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights a...
Newron Pharmaceuticals SpA
About the publication
More Newron Pharmaceuticals S.p.A. related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN